KR102636166B1 - GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체 - Google Patents

GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체 Download PDF

Info

Publication number
KR102636166B1
KR102636166B1 KR1020197031368A KR20197031368A KR102636166B1 KR 102636166 B1 KR102636166 B1 KR 102636166B1 KR 1020197031368 A KR1020197031368 A KR 1020197031368A KR 20197031368 A KR20197031368 A KR 20197031368A KR 102636166 B1 KR102636166 B1 KR 102636166B1
Authority
KR
South Korea
Prior art keywords
optionally substituted
delete delete
alkyl
halo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197031368A
Other languages
English (en)
Korean (ko)
Other versions
KR20190140936A (ko
Inventor
제인 브라운
스티븐 코널리
스테픈 브이. 에프. 한센
개빈 밀른
바랏 쉼푸케이드
돈 스미스
제라드 토마스
트론드 울븐
마트야스 브르바르
아론 릭비
Original Assignee
캘단 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 캘단 테라퓨틱스 리미티드 filed Critical 캘단 테라퓨틱스 리미티드
Publication of KR20190140936A publication Critical patent/KR20190140936A/ko
Application granted granted Critical
Publication of KR102636166B1 publication Critical patent/KR102636166B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1020197031368A 2017-03-24 2018-03-26 GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체 Active KR102636166B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1704714.3 2017-03-24
GBGB1704714.3A GB201704714D0 (en) 2017-03-24 2017-03-24 Pharmaceutical compounds
PCT/GB2018/000047 WO2018172727A1 (en) 2017-03-24 2018-03-26 Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators

Publications (2)

Publication Number Publication Date
KR20190140936A KR20190140936A (ko) 2019-12-20
KR102636166B1 true KR102636166B1 (ko) 2024-02-13

Family

ID=58687800

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197031368A Active KR102636166B1 (ko) 2017-03-24 2018-03-26 GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체

Country Status (12)

Country Link
US (1) US11220483B2 (https=)
EP (1) EP3601229B1 (https=)
JP (1) JP7099672B2 (https=)
KR (1) KR102636166B1 (https=)
CN (1) CN110891938B (https=)
AU (1) AU2018238102B2 (https=)
BR (1) BR112019019868A2 (https=)
CA (1) CA3057415A1 (https=)
GB (1) GB201704714D0 (https=)
MX (1) MX394818B (https=)
WO (1) WO2018172727A1 (https=)
ZA (1) ZA201906873B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
IL295825A (en) 2020-02-28 2022-10-01 Kallyope Inc gpr40 agonists
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用
WO2022076503A1 (en) * 2020-10-08 2022-04-14 Eli Lilly And Company 6-methoxy-3,4-dihydro-1h-isoquinoline compounds useful in the treatment of diabetes
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
KR102605163B1 (ko) * 2021-06-01 2023-11-23 연세대학교 산학협력단 뇌암의 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053446A2 (en) 2006-11-02 2008-05-08 Piramal Life Sciences Limited Benzoxazepine compounds, their preparation and use
WO2016105118A2 (ko) 2014-12-24 2016-06-30 주식회사 엘지생명과학 Gpr120 효능제로서의 바이아릴 유도체

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005282721A1 (en) * 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
AU2006279548A1 (en) 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
CA2627682A1 (en) 2006-01-30 2007-08-09 Irm Llc Polycyclic 1, 2, 3, 4 -tetrahydro- isoquinoline derivatives and compositions comprising them as ppar modulators
JP2010519258A (ja) 2007-02-22 2010-06-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Gタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体
WO2009147990A1 (ja) * 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体
EP2736330A4 (en) 2011-07-29 2015-05-27 Tempero Pharmaceuticals Inc COMPOUNDS AND METHODS
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053446A2 (en) 2006-11-02 2008-05-08 Piramal Life Sciences Limited Benzoxazepine compounds, their preparation and use
WO2016105118A2 (ko) 2014-12-24 2016-06-30 주식회사 엘지생명과학 Gpr120 효능제로서의 바이아릴 유도체

Also Published As

Publication number Publication date
CA3057415A1 (en) 2018-09-27
AU2018238102A1 (en) 2019-10-31
AU2018238102B2 (en) 2021-11-04
JP7099672B2 (ja) 2022-07-12
JP2020515636A (ja) 2020-05-28
ZA201906873B (en) 2022-03-30
EP3601229B1 (en) 2024-11-06
US20200317619A1 (en) 2020-10-08
MX394818B (es) 2025-03-24
AU2018238102A2 (en) 2019-11-07
US11220483B2 (en) 2022-01-11
KR20190140936A (ko) 2019-12-20
CN110891938B (zh) 2023-10-31
RU2019133659A3 (https=) 2021-07-16
BR112019019868A2 (pt) 2020-04-22
GB201704714D0 (en) 2017-05-10
WO2018172727A1 (en) 2018-09-27
EP3601229A1 (en) 2020-02-05
MX2019011314A (es) 2020-01-27
CN110891938A (zh) 2020-03-17
RU2019133659A (ru) 2021-04-26

Similar Documents

Publication Publication Date Title
KR102636166B1 (ko) GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체
JP6163695B2 (ja) 新しいインダニルオキシフェニルシクロプロパンカルボン酸
CN111440189B (zh) 稠环嘧啶氨基衍生物、其制备方法、中间体、药物组合物及应用
EP3154954B1 (en) Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
WO2018006795A1 (zh) 芳香乙炔或芳香乙烯类化合物、其中间体、制备方法、药物组合物及应用
JP6441928B2 (ja) 新規インダニルオキシフェニルシクロプロパンカルボン酸
TW202003466A (zh) 人類整合素α4β7拮抗劑
KR20120003941A (ko) 신규 갑상선 호르몬 β 수용체 작동약
WO2016022448A1 (en) Antidiabetic bicyclic compounds
KR20190034318A (ko) Ido1억제제 및 이의 제조방법과 응용
CA2891535A1 (en) Dihydropyrazole gpr40 modulators
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
KR20210082466A (ko) 샤페론-매개 자가포식작용 조절제로서 유용한 벤족사졸 및 관련된 화합물
CN112898289B (zh) 调节fxr活性的化合物及其应用
KR19990007203A (ko) 아포 비-분비/엠티피 억제제 하이드로클로라이드 염
CN109651208B (zh) N-芳基磺酰胺类化合物,其药物组合物及其用途
CN103145663B (zh) (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物,其制备方法及其在医药上的应用
CN109748914B (zh) 吡啶并嘧啶类化合物及其应用
WO2018219204A1 (zh) 一类新型苯氧乙酸衍生物、其制备方法及其作为药物的用途
TW201313684A (zh) 氮雜螺烷烴化合物
JP2025504791A (ja) ヒドロキシフェニル部分を含む化合物及びその使用
RU2776801C2 (ru) Производные тетрагидробензо[d]азапена в качестве модуляторов as gpr120
EP3129345A1 (en) Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
HK40085749A (en) P2x3 modulators
IL317522A (en) Compounds, preparations and methods of using them

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191023

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201224

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230603

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230822

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231124

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240207

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240207

End annual number: 3

Start annual number: 1

PG1601 Publication of registration